110 related articles for article (PubMed ID: 34949180)
1. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
[TBL] [Abstract][Full Text] [Related]
3. mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene therapy.
Liu Y; Lin Y; Xiao H; Fu Z; Zhu X; Chen X; Li C; Ding C; Lu C
J Control Release; 2024 May; 369():765-774. PubMed ID: 38593976
[TBL] [Abstract][Full Text] [Related]
4. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer.
McFadden M; Singh SK; Kinnel B; Varambally S; Singh R
J Ovarian Res; 2023 Nov; 16(1):220. PubMed ID: 37990267
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein.
Mello FVC; de Moraes GN; Maia RC; Kyeremateng J; Iram SH; Santos-Oliveira R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290047
[TBL] [Abstract][Full Text] [Related]
6. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
7. A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells.
Baek JS; Cho CW
Oncotarget; 2017 May; 8(18):30369-30382. PubMed ID: 28423731
[TBL] [Abstract][Full Text] [Related]
8. A convenient protonated strategy for constructing nanodrugs from hydrophobic drug-inhibitor conjugates to reverse tumor multidrug resistance.
Wang P; Wang Y; Xia X; Wu J; Lin J; Huang W; Yan D
Nanoscale; 2024 May; 16(17):8434-8446. PubMed ID: 38592819
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein antibody-conjugated paclitaxel liposomes targeted for multidrug-resistant lung cancer.
Wang J; Suo X; Zhang H
Nanomedicine (Lond); 2023 Apr; 18(10):819-831. PubMed ID: 37306214
[No Abstract] [Full Text] [Related]
10. Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles induces proliferation inhibition and apoptosis in ovarian cancer cells.
Liu H; Chang S; Sun J; Zhu S; Pu C; Zhu Y; Wang Z; Xu RX
Mol Pharm; 2014 Jan; 11(1):40-8. PubMed ID: 24266423
[TBL] [Abstract][Full Text] [Related]
11. Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy.
Tang L; Wang YJ; Wang YY; Li ST; Kong L; Li XT; Ma LL; Liu XX
Int J Nanomedicine; 2024; 19():5193-5211. PubMed ID: 38859958
[TBL] [Abstract][Full Text] [Related]
12. Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.
Yu X; Yang G; Shi Y; Su C; Liu M; Feng B; Zhao L
Int J Nanomedicine; 2015; 10():7045-56. PubMed ID: 26648717
[TBL] [Abstract][Full Text] [Related]
13. Engineering extracellular vesicles mimetics for targeted chemotherapy of drug-resistant ovary cancer.
Liu X; Liu G; Mao Y; Luo J; Cao Y; Tan W; Li W; Yu H; Jia X; Li H
Nanomedicine (Lond); 2024 Jan; 19(1):25-41. PubMed ID: 38059464
[TBL] [Abstract][Full Text] [Related]
14. The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.
Li QQ; Cao XX; Xu JD; Chen Q; Wang WJ; Tang F; Chen ZQ; Liu XP; Xu ZD
Cell Mol Life Sci; 2009 Feb; 66(3):504-15. PubMed ID: 19099191
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Kawaguchi W; Itamochi H; Kigawa J; Kanamori Y; Oishi T; Shimada M; Sato S; Shimogai R; Sato S; Terakawa N
Cancer Sci; 2007 Dec; 98(12):2002-8. PubMed ID: 17900261
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.
Reddy TL; Garikapati KR; Reddy SG; Reddy BV; Yadav JS; Bhadra U; Bhadra MP
Sci Rep; 2016 Oct; 6():35223. PubMed ID: 27786239
[TBL] [Abstract][Full Text] [Related]
17. Multimodal Nanoplatform with ROS Amplification to Overcome Multidrug Resistance in Prostate Cancer via Targeting P-Glycoprotein and Ferroptosis.
Guan Y; Lei H; Xing C; Yan B; Lin B; Yang X; Huang H; Kang Y; Pang J
Adv Healthc Mater; 2024 Jan; 13(3):e2301345. PubMed ID: 37855250
[TBL] [Abstract][Full Text] [Related]
18. Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo.
Yu KH; Kuo CY; Wu IT; Chi CH; Tsai KC; Kuo PC; Zeng JW; Hung CC; Hung HY
Eur J Pharmacol; 2023 Dec; 960():176146. PubMed ID: 37884184
[TBL] [Abstract][Full Text] [Related]
19. The
Yin B; Lu P; Liang J; Zhang W; Xin M; Pei K; Li Y
J Int Med Res; 2019 Oct; 47(10):5256-5269. PubMed ID: 31638462
[TBL] [Abstract][Full Text] [Related]
20. Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles.
Rodzinski A; Guduru R; Liang P; Hadjikhani A; Stewart T; Stimphil E; Runowicz C; Cote R; Altman N; Datar R; Khizroev S
Sci Rep; 2016 Feb; 6():20867. PubMed ID: 26875783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
